Short answer
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed its fiscal 2026 10-K annual report with the SEC on Nov 12, 2026. It reported revenue of $451M (−45.6% year over year) and net income of −$724M.
- Top risk flagged: FDA approval risk: plozasiran sNDA for sHTG remains pending despite STAR pilot entry
FY2026 key financial metrics · XBRL
- Revenue
- $451M
- −45.6% YoY
- Net income
- −$724M
- −44302.6% YoY
- Operating margin
- -156.9%
- −168.7 pp YoY
- EPS (diluted)
- −$5.11
- −51000.0% YoY
- ROE
- -1439.4%
- −1439.1 pp YoY
- Operating cash flow
- −$272M
- −251.5% YoY
Source: XBRL data from the ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 10-K on SEC EDGAR. USD.
ARROWHEAD PHARMACEUTICALS, INC. FY2026 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- RNAi biopharmaceutical model: proprietary TRiM platform develops gene-silencing medicines, with partnered programs funding wholly owned assets
- First commercial product REDEMPLO launched in 2025, with approvals expanded to the EU, Canada, Australia, China and UK
- Strategic shift toward commercialization: commercial organization built for FCS and larger footprint planned for potential sHTG launch in Q2 2027
- Plozasiran Phase 3 results: median triglyceride reductions of 79% and 81% at Month 12, with STAR pilot acceptance for the sNDA
- Workforce expanded to 1,062 employees across the United States, Switzerland and New Zealand, supporting commercialization, manufacturing and R&D growth
Management Discussion & Analysis
- Revenue $450.8M, down $378.6M YoY from $829.4M, driven by lower Sarepta and Sanofi collaboration revenue
- Net loss $724.2M vs $1.6M; operating loss $707.2M vs operating income $98.3M
- Best performer: Sarepta revenue $316.9M; worst: Sanofi revenue $13.3M, down from $130.0M
- Operating cash flow $(271.9)M; capex $12.0M; PRV purchase $215.0M; convertible-note proceeds $681.3M
- Outlook: liquidity sufficient for at least 12 months; planned U.S. sHTG launch in Q2 2027 pending approval
Risk Factors
- FDA approval risk: plozasiran sNDA for sHTG remains pending despite STAR pilot entry
- Pricing pressure: CMS GLOBE Medicare Part B model begins in 2027 and faces pending litigation
- Supply-chain exposure: reliance on third parties in China creates BIOSECURE Act and tariff disruption risk
- Competitive disruption: generic REDEMPLO versions could erode sales if exclusivity is inadequate
- Leverage constraint: Sixth Street financing agreement could accelerate debt repayment upon covenant breach
Generated from the filing text; verify against the original. How to read a 10-K
Other ARROWHEAD PHARMACEUTICALS, INC. annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.